Fig. 4: Biomarker analysis of ctDNA.

a, Shown is the KRAS G12C VAF at baseline (C1D1) and early treatment time points (C1D15, C3D1) among patients with a detectable KRAS G12C mutation from cfDNA at C1D1 (n = 20 shown, each line represents one patient). Two patients with missing C1D15 plasma samples are not shown in the plot. Box-and-whisker plots at each time point in each indication show the median (center line) with the minima and maxima box boundaries representing the 25th and 75th percentiles; whiskers represent the minimum and maximum values of the data that are within 1.5 times the interquartile range under the 25th and over the 75th percentiles. b, Shown are putative genetic mechanisms of acquired resistance to divarasib plus cetuximab combination treatment among 14 patients who had an EoT visit before 01 May 2023. Each row represents one patient with the first four columns describing assigned divarasib dose, best response, PFS, prior KRAS G12C inhibitor use and subsequent columns indicating acquired genomic alterations at EoT.